The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  McCrone, Paul ^a   Payan, Christine Anne Mary ^b   Knapp, Martin ^a,c   Ludolph, Albert ^d   Agid, Yves ^e   Leigh, P Nigel ^f   Bensimon, Gilbert ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d UNIVERSITY OF ULM   (Germany)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; EDUCATIONAL STATUS; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGRESSIVE SUPRANUCLEAR PALSY; RATING SCALE; SCORING SYSTEM; SHY DRAGER SYNDROME; UNITED KINGDOM; ECONOMICS; HEALTH SERVICE; HOSPITALIZATION; MIDDLE AGED; UTILIZATION REVIEW;

AGED; FEMALE; FRANCE; GERMANY; GREAT BRITAIN; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 80052539342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024369     Document Type: Article

References (37)

1. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, et al. (1996) Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 60: 615-620.
2. Testa D, Filippini G, Farinotti M, Palazzini E, Caraceni T, (1996) Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol 243: 401-404.
3. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, et al. (2001) Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 22: 247-251.
4. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP, (1997) Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 48: 384-393.
5. Schrag A, Ben-Shlomo B, Quinn NP, (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354: 1771-1775.
6. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y, (2008) Survival in multiple system atrophy. Mov Disord 23: 294-296.
7. Litvan I, (2003) Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord 18 (Suppl. 6): S43-S50.
8. Golbe LI, Ohman-Strickland PA, (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130: 1552-1565.
9. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC, (1988) Prevalence and natural history of progressive supranuclear palsy. Neurology 38: 1031-1034.
10. Bower JH, Maraganore DM, McDonnell SK, Rocca WA, (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49: 1284-1288.
11. Nath U, Burn DJ, (2000) The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Parkinsonism Relat Disord 6: 145-153.
12. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, et al. (2001) The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 124: 1438-1449.
13. Vanacore N, Bonifati V, Colosimo C, Fabbrini G, De Michele G, et al. (2001) Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 22: 101-103.
14. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, et al. (2001) Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 22: 97-99.
15. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, et al. (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125: 1070-1083.
16. European Commission (2010) Eurostat. Available: http://epp.eurostat.ec.europa.eu/portal/page/portal/population/introduction Accessed 2011 Aug 15.
17. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, et al. (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study. Brain 132: 156-171.
18. Beecham J, Knapp M, (2001) Costing psychiatric interventions. In: Thornicroft G, editors. Measuring mental health needs London Gaskell pp. 200-224.
19. Hoehn MM, Yahr MD, (1967) Parkinsonism: onset, progression, and mortality. Neurology 17: 427-442.
20. Guy W, (1976) ECDEU Assessment for Psychopharmacology, revised edition Rockville, MD NIMH publications.
21. Payan CAM, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, et al. (2011) Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS - parkinson plus scale. PLoS One pp. 6 Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022293 Accessed 2011 Aug 15.
22. Ware JE, Sherbourne CD, (1992) The MOS 36-item Short-Form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30: 473-483.
23. Netten A, Curtis L, (2003) Unit costs of health and social care Canterbury Personal Social Services Research Unit.
24. Hutton J, (2001) Unit costs for multi-country economic evaluations. In: Netten A, Rees T, Harrison G, editors. Unit costs of health and social care Canterbury Personal Social Services Research Unit pp. 31-34.
25. OECD Statistics Portal. Available: http://www.oecd.org/statsportal/0,3352,en_2825_293564_1_1_1_1_1,00.html Accessed 2011 Aug 15.
26. Anderson R, Newman JF, (1973) Societal and individual determinants of medical care utilization in the United States. Milbank Memorial Fund Quarterly 51: 95-124.
27. O'Hagan A, Stevens JW, (2003) Assessing and comparing costs: How robust are the bootstrap and methods based on asymptotic normality? Health Econ 12: 33-49.
28. McCrone P, Heslin M, Knapp M, Bull P, Thompson A, (2008) Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 26: 847-860.
29. Kobelt G, Lindgren P, Smala A, Jönsson B, (2000) German Cost of MS Study Group. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany Stockholm Stockholm School of Economics.
30. Lowin A, Knapp M, McCrone P, (2001) Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psych 16: 1143-1148.
31. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, et al. (2002) Comparing patterns and costs of schizophrenia care in five European countries: The EPSILON study. Acta Psychiat Scand 105: 42-54.
32. McCrone P, (2009) Capturing the costs of end of life care: comparisons of multiple sclerosis, Parkinson's disease and dementia. J Pain Symptom Manag 38: 62-67.
33. Calsyn RJ, Allen G, Morse GA, Smith R, Templehoff B, (1993) Can you trust self-report data provided by homeless mentally ill individuals? Evaluation Rev 17: 353-366.
34. Goldberg RW, Seybolt DC, Lehman A, (2002) Reliable self-report of health service use by individuals with serious mental illness. Psychiatr Serv 53: 879-881.
35. Patel A, Rendu A, Moran P, Leese M, Mann A, et al. (2004) A comparison of two methods of collecting economic data in primary care. Fam Pract 22: 323-327.
36. Kennedy ADM, Leigh-Brown AP, Torgerson DJ, Campbell J, Grant A, (2002) Resource use data by patient report or hospital records: Do they agree? BMC Health Services Research 2 Available: http://www.biomedcentral.com/1472-6963/2/2 Accessed: 2011 Aug 15.
37. Mirandola M, Bisoffi G, Bonizzato P, Amaddeo F, (1999) Collecting psychiatric resources utilisation data to calculate costs of care: a comparison between a service receipt interview and a case register. Soc Psych Psych Epid 34: 341-347.